TrialBMJ open2021

Repurposing bromocriptine for Aβ metabolism in Alzheimer's disease (REBRAnD) study: randomised placebo-controlled double-blind comparative trial and open-label extension trial to investigate the safety and efficacy of bromocriptine in Alzheimer's disease with presenilin 1 (PSEN1) mutations.

Takayuki Kondo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.